| Name | Indivior |
|---|---|
| Epic | INDV |
| Isin | GB00BN4HT335 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 858.50p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1,086.23 | Debt ratio | n/a |
| Shares in issue | 134.43 | Debt-to-equity ratio | n/a |
| P/E ratio | 1473.7 | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -7.02 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | 1 | 52-week high / low | 576.50p / 1,764.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Indivior |
|---|---|
| Address | 234 Bath Road, Slough, Berkshire, United Kingdom, SL1 4EE |
| Telephone | |
| Website | http://www.Indivior.com |
| Director | Position |
|---|---|
| Mr Mark Crossley | CEO |
| Mr Graham Hetherington | Chairman |
| Mr Jerome Lande | Non-Executive Director |
| Ms Juliet Thompson | Senior Independent Director |
| Mr Keith Humphreys | Independent Non-Executive Director |
| Mr Peter Bains | Independent Non-Executive Director |
| Mr Jo Le Couilliard | Independent Non-Executive Director |
| Ms Barbara Ryan | Independent Non-Executive Director |
| Mr David E. Wheadon | Independent Non-Executive Director |
| Mr Mark Stejbach | Independent Non-Executive Director |
| Mr Ryan Preblick | CFO & Executive Director |
| Assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 237 | 70 | 82 |
| Investments and other non-current assets | 41 | 98 | n/a |
| Total non-current assets | 691 | 510 | 388 |
| Inventory / work in progress | 142 | 114 | 95 |
| Trade and other receivables | 254 | 225 | 215 |
| Cash and equivalents | 316 | 774 | 1102 |
| Other current assets and asset held for resale | 457 | 27 | 32 |
| Total of all assets | 1954 | 1769 | 1832 |
| Liabilities $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 1305 | 1019 | 804 |
| Long term liabilities | 649 | 699 | 825 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 1954 | 1718 | 1629 |
| Net assets $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | n/a | 51 | 203 |
| Equity $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 68 | 68 | 70 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | 1244 | 1303 | 1438 |
| Share premium account | 11 | 8 | 7 |
| Total equity | n/a | 51 | 203 |
| Income $ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -4 | -85 | 213 |
| Pre-tax profit | 1 | -95 | 190 |